Please login to the form below

Not currently logged in
Email:
Password:

Eisai pairs with Ajinomoto to form GI specialist EA Pharma

Newcompany will begin operations in April 2016

Eisai

Eisai and Ajinomoto have agreed to pool their resources in gastrointestinal pharmaceuticals to form a specialist company called EA Pharma.

The new organisation - which will be jointly owned by Eisai and food and pharma group Ajinomoto in a 60:40 split - aims to become the leading GI company in Japan and tap into the expanding GI therapy market resulting from the ageing world population and rising rates of autoimmune diseases such as Crohn's.

Under the terms of the deal, Eisai's GI unit - which sells drugs such as Pariet (rabeprazole) and Selbex (teprenone) - will be combined with Ajinomoto's pharmaceutical subsidiary, which has developed drugs such as alcoholic liver disease therapy Livact/Livamin (leucine, isoleucine and valine)  and also focuses on contract manufacturing as well as researching new GI therapies.

The two companies already have an existing working relationship, as Eisai is the licensee for Livamin in a number of markets including China and Hong Kong.

EA Pharma is due to start operating on April 1, 2016, with Ajinomoto Pharma's chief executive Takashi Nagamachi serving as chairman and Eisai's corporate officer Hajime Shimizu taking on the role of president. 

Akira Shinji - another Ajinomoto executive - has been named as the new company's managing director, and the company will have around 1,250 employees.

The combined company will have a product line-up that "comprehensively covers the upper and lower digestive tract, as well as the liver and pancreas", according to documents explaining the rationale for the merger.

The combined pipeline includes several projects in late-stage testing - including E3810, a new formulation of rabeprazole for reflux oesophagitis, oral alpha 4 integrin antagonist AJM300 for ulcerative colitis and IBAT inhibitor AJG533 for chronic constipation. 

In addition, a new Crohn's disease candidate E6011 (an anti-fractalkine antibody) coming through phase II testing.

Article by
Phil Taylor

15th October 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...